XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration and License Agreements (Tables)
 9 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Revenue
The following table provides a summary of revenue recognized:
Three Months Ended June 30,Nine Months Ended June 30,
2024202320242023
(in thousands)
GSK$— $277 $2,685 $29,600 
Horizon— 1,539 — 23,206 
Takeda— 14,009 866 146,477 
Janssen— — — 355 
Amgen— — — 25,000 
Total$— $15,825 $3,551 $224,638 
Schedule of Receivables and Contract Liabilities
The following table summarizes the balance of receivables and contract liabilities related to the Company’s
collaboration and license agreements:
June 30, 2024September 30, 2023
(in thousands)
Receivables included in accounts receivable$— $— 
Contract liabilities included in deferred revenue$— $866